Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
According to a study by M
HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
Food & Drug Administration (FDA) includes epitalon in its group of peptides that pose a risk of immunogenicity, in which the body reacts to a substance as though it were a threat and mounts an immune response against it.37 The FDA warns that such immune responses can be life-threatening, so epitalon isnt completely safe for everyone.38 In addition, the healthcare providers weve consulted suggest that women who are pregnant or breastfeeding should avoid epitalon, along with other therapeutic peptides, since there isnt enough research to confirm safety for them or their fetus/child
Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations
